
News|Articles|July 1, 2012
Pipeline Preview
Recent FDA action (through June 2012) related to, Darunavir, Prezista, Janssen Therapeutics, Ridaforolimus, Merck, Tafamidis meglumine, Pfizer, mechlorethamine, Ceptaris Therapeutics, AVP-923, Avanir Pharmaceuticals, NKTR-181, Nektar Therapeutics, EDI200, Edimer Pharmaceuticals, Galeterone, TOK-001, Tokai Pharmaceuticals, Butoconazole nitrate 2% vaginal cream, Gynazole-1, Perrigo
Advertisement
Complete response
Priority review
Fast-track designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sponsored: The Teva Biosimilars Trend Report
2
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
3
The 6-Year Cure Threshold: Redefining Cure for Colon Cancer Survivors
4
Medicaid Unwinding Drops Coverage for Millions but Uninsured Rate Remains Steady
5